21 related articles for article (PubMed ID: 2462408)
1. Lighting the torch: intratumoural T cell-to-stroma enrichment score as a predictor of immunotherapy response in urothelial carcinoma.
Aggen DH; Rosenberg JE
Nat Rev Clin Oncol; 2024 Jul; 21(7):487-488. PubMed ID: 38622410
[No Abstract] [Full Text] [Related]
2. [Contribution of monoclonal antibodies within the framework of urothelial tumors of the bladder].
Chopin DK
Pathol Biol (Paris); 1988 Apr; 36(4):301-8. PubMed ID: 3287299
[TBL] [Abstract][Full Text] [Related]
3. [Urinary BTA-TRAK in the follow-up of superficial transitional-cell bladder carcinoma].
Fernández Gómez JM; García Rodríguez J; Escaf Barmadah S; Raigoso P; Rodríguez Martínez JJ; Allende MT; Casasola Chamorro J; Rodríguez Faba O; Martín Benito JL; Regadera Sejas FJ
Arch Esp Urol; 2002; 55(1):41-9. PubMed ID: 11957750
[TBL] [Abstract][Full Text] [Related]
4. Editorial comment on: immunoreactivity of p63 in monolayered and in vitro stratified human urothelial cell cultures compared with native urothelial tissue.
Papatsoris A; Deliveliotis C
Eur Urol; 2008 May; 53(5):1073. PubMed ID: 17980953
[No Abstract] [Full Text] [Related]
5. Human transitional cell carcinoma in the NMRI-nu/nu mouse bladder: a new animal model for the in vivo use of monoclonal antibodies and cytotoxic agents.
Huland E; Arndt R; Huland H
Cancer Res; 1986 May; 46(5):2488-9. PubMed ID: 3697989
[TBL] [Abstract][Full Text] [Related]
6. Lewis X antigen immunostaining in the diagnosis of transitional cell carcinoma.
Loy TS; Alexander CJ; Calaluce RD
Mod Pathol; 1995 Aug; 8(6):587-90. PubMed ID: 8532688
[TBL] [Abstract][Full Text] [Related]
7. [Update 2016 - Immunotherapy for urothelial carcinoma].
Retz M; Gschwend JE; Schmid SC
Urologe A; 2016 Feb; 55(2):246-52. PubMed ID: 26767648
[TBL] [Abstract][Full Text] [Related]
8. [Urothelial tumor markers: update].
de Castro F; Rosell D; Agüera LG; Isa W; Sánchez de la Muela P; Robles JE; Zudaire JJ; Berián JM
Rev Med Univ Navarra; 1990; 34(3):167-71. PubMed ID: 2101497
[TBL] [Abstract][Full Text] [Related]
9. [Immunolabelling of urothelial bladder tumors. Value of 2 monoclonal antibodies and perspective in cytology].
Pluot M; Bahroum K; Joundi A; Ducrot P; Diebold MD
Arch Anat Cytol Pathol; 1988; 36(3):69-74. PubMed ID: 2462408
[No Abstract] [Full Text] [Related]
10. Advances in the diagnosis of urothelial neoplasia.
Crissman JD; Zarbo RJ; Johnson T; Babu VR; Sarkar FH; Miles BJ; Cerny JC
Henry Ford Hosp Med J; 1989; 37(1):19-23. PubMed ID: 2670840
[TBL] [Abstract][Full Text] [Related]
11.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
12.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
13.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
14.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
15.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
16.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
